GLP-1RA non-responders: tackling a hidden challenge behind the obesity epidemic - Pharmaceutical Technology

Improving outcomes for patients classed as ‘non-responders’ to GLP-1RA drugs remains a key unmet need within the obesity space. Improving outcomes for patients classed as ‘non-responders’ remains a key unmet need within the obesity space. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news and procurement in the pharmaceutical industry

Source: Pharmaceutical Technology